MedTrace Logo

Efficacy of Co-Spinal Ondansetron In Inguinal Herniorrhaphy

NCT06850740 · Status: ENROLLING_BY_INVITATION · Phase: NA · Type: INTERVENTIONAL · Enrollment: 46

Last updated 2025-04-30

No results posted yet for this study

Summary

Ondansetron, a selective serotonin 5-HT3 receptor antagonist, is well known for its antiemetic effects. However, its ability to reduce hypotension during spinal anesthesia has recently sparked great interest. In clinical practice, administering ondansetron before spinal anesthesia has produced promising results.

Conditions

  • Hernia, Inguinal

Interventions

DRUG

Ondansetron 8mg

Patients will receive 8 mg of ondansetron (ZOFATRONE®, 8 mg/4 mL, EVA Pharma, Egypt)

DRUG

Normal Saline

Patients will be managed by administering 100 ml of normal saline solution as placebo

Sponsors & Collaborators

  • Suez Canal University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-03-15
Primary Completion
2025-06-15
Completion
2025-08-15

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06850740 on ClinicalTrials.gov